Recombinant Human Pentraxin 2 vs Placebo and Lung Function in Idiopathic Pulmonary Fibrosis

This randomized clinical trial compares the effects of recombinant human pentraxin 2, a monocyte differentiation inhibitor, vs placebo on changes in percent predicted forced vital capacity after 28 weeks in patients with idiopathic pulmonary fibrosis.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research